Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management is executing a planned leadership transition, elevating Ryan Cohlhepp to CEO to leverage his commercial oncology experience as the company nears potential launch.
The company's strategic focus remains on the pivotal Phase III FORTIFI-HN01 study for HPV-negative head and neck cancer, which is on track for substantial enrollment by year-end.
Three-year follow-up data presented at ASCO 2026 demonstrated that TGF-beta inhibition nearly doubled overall survival versus standard of care pembrolizumab in the pivotal dose cohort.
Management attributes clinical success to the mechanistic foundation of TGF-beta inhibition, which drives deeper tumor penetration and immune cell infiltration compared to standard EGFR-directed therapies.
#management #year
Management is executing a planned leadership transition, elevating Ryan Cohlhepp to CEO to leverage his commercial oncology experience as the company nears potential launch.
The company's strategic focus remains on the pivotal Phase III FORTIFI-HN01 study for HPV-negative head and neck cancer, which is on track for substantial enrollment by year-end.
Three-year follow-up data presented at ASCO 2026 demonstrated that TGF-beta inhibition nearly doubled overall survival versus standard of care pembrolizumab in the pivotal dose cohort.
Management attributes clinical success to the mechanistic foundation of TGF-beta inhibition, which drives deeper tumor penetration and immune cell infiltration compared to standard EGFR-directed therapies.
#management #year
3 days ago
